This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Analysis of effectiveness
The analysis of effectiveness was based on intention to treat. The primary health outcome was the number of HIV preventable cases.
Effectiveness results
The number of HIV preventable cases was 55 (47 HIV carriers with an average new HIV per HIV infected individual of 0.17. From this 47 HIV positive partners, another 8 could be traced).
Modelling
Not considered.
Outcomes assessed in the review
Effectiveness estimates derived from a review were the average new HIV per HIV infected individual, initial T4 cell distribution of the carrier and life expectancy of the HIV infected individuals according to the T4 cell distribution.
Study designs and other criteria for inclusion in the review
No specific study designs were stipulated by the authors as inclusion/exclusion criteria.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
10 studies were included in the review.
Methods of combining primary studies
Narrative method.
Investigation of differences between primary studies
Not undertaken.
Results of the review
The average new HIV per HIV infected individual was 0.17. The initial T4 cell distribution of the carrier was T4 > 500 cells/mm?3, 59%; T4 = 201-500 cells/mm?3, 36.4%; and T4 < 200 cells/mm?3, 4.6%. Life expectancy of the HIV infected individuals according to the T4 cell distribution was 10.75 years, 9 years and 2 years, respectively.
